NEWS & EVENTS
Noema Pharma to Present at Two Upcoming Conferences
BASEL, Switzerland, January 3, 2024 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of management ...
Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer
— Appointment supports Noema’s robust clinical-stage pipeline addressing high value CNS disorders — BASEL, Switzerland, November 15, 2023 — Noema Pharma, a clinical-stage biotech company ...
Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer
Company is well-positioned to advance robust clinical-stage CNS pipeline, following oversubscribed Series B financing earlier this year BASEL, Switzerland, June 21, 2023 – Noema Pharma, ...
Noema Pharma to Present at BioEquity Europe 2023
BASEL, Switzerland, May 9, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members of ...
Noema Pharma raises CHF 103 million (USD 112 million) in Series B financing round led by Forbion and Jeito Capital
Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disorders Nanna Lüneborg, General Partner at Forbion and Rachel Mears, ...
NOEMA PHARMA TO ATTEND AND PRESENT AT 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE IN SAN FRANCISCO
BASEL, Switzerland and BOSTON, Massachusetts, January 5, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members ...
Noema Pharma receives FDA Fast Track designation
BASEL, Switzerland, October 18, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food ...
Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation studY
Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgia LIBRATN (NOE-101 Phase 2/3 ...
Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 ...
Noema Pharma announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b study of PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder
Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, ...
Noema Pharma to attend and present at BioEquity Europe and UBS Global Healthcare Conference in May 2022
BASEL, Switzerland, May 6, 2022 – Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi Costa, Chief Executive ...
Noema Pharma appoints Michael Gutch as Chief Financial Officer
BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of ...
Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical ...
Noema Pharma announces publication of “Noema, Basimglurant and a New Clinical Trial for Seizures in TSC” podcast on TSC Alliance website
BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces that the TSC ...
Noema Pharma announces FDA Investigational New Drug authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 14, 2022 – Noema Pharma, a Swiss-based clinical ...
Trigeminal Neuralgia – You are not alone, Hosted by Noema Pharma
BASEL, Switzerland, February 8, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will ...
Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering
BASEL, Switzerland, December 8, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will ...
Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo
BASEL, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of ...
Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors
BASEL, Switzerland, October 4, 2021 –Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of ...
Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021
BASEL, Switzerland, September 2, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend ...
Noema Pharma initiates Phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome
First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel, ...
Noema Pharma to Host a Key Opinion Leader Webinar on Seizures in Tuberous Sclerosis Complex
BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion ...
Noema Pharma to Attend Investor Conferences in June and July 2021
BASEL, Switzerland, May 31, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend ...